- Home
- RIV vs NGNE Comparison
RIV vs NGNE Comparison
Compare RIV & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIV | NGNE |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.1M | 327.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | RIV | NGNE |
|---|---|---|
| Price | $11.71 | $26.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $63.57 |
| AVG Volume (30 Days) | 69.5K | ★ 143.1K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 12.85% | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.93 | $11.78 |
| 52 Week High | $12.56 | $37.27 |
Technical Indicators
Market Signals| Indicator | RIV | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 60.88 | 60.96 |
| Support Level | $11.57 | $19.40 |
| Resistance Level | $11.74 | $29.05 |
| Average True Range (ATR) | 0.14 | 1.93 |
| MACD | 0.03 | 0.23 |
| Stochastic Oscillator | 83.52 | 74.39 |
Price Performance
Historical ComparisonAbout RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.